Why Proof-of-Concept Funding Is the Leverage Point Nobody Talks About

Most technology transfer offices spend enormous energy on two ends of the commercialization process: protecting IP on one side, closing deals on the other. What happens in the middle gets treated like someone else's problem.

Photo by Markus Winkler on Pexels.

That middle is proof-of-concept (POC) funding, the small, targeted investment made to take a lab result from "this is interesting" to "this is investable." And the gap it fills is not subtle. Industry partners won't license technology that hasn't demonstrated basic feasibility outside the lab notebook. Investors won't fund a spinout built on a single published result. Yet most universities have no systematic way to bridge that gap.

What Proof-of-Concept Funding Actually Does

Let's be precise about what we're talking about. POC funding is not early-stage R&D. It's not a research grant with a commercialization checkbox. Done well, it's a de-risking exercise, a short-duration, milestone-driven investment designed to answer one or two questions that a real buyer or investor would ask before writing a check.

Those questions vary by technology. For a medical device, the question might be: does this prototype perform comparably to the current standard in a bench model? For a software tool built on a university algorithm, it might be: can this run on hardware a customer actually owns? Small questions. Answerable in six to eighteen months. But without answers, the technology sits.

Programs like the Deshpande Center at MIT and the von Liebig Center at UC San Diego proved the model works. Both showed measurable increases in licensing activity and spinout formation after targeted POC investment, not because the science got better, but because the story got better. Investors and licensees respond to evidence, not potential.

Why Most Institutions Underinvest Here

The honest answer is incentive misalignment. Federal research grants fund discovery. SBIR/STTR funding is designed for small businesses, which usually don't exist yet at the POC stage. Philanthropic gifts often come with donor preferences attached. None of these fit cleanly.

University internal funds exist in some places, but they're often undercapitalized, slow-moving, or evaluated by committees that reward academic rigor over commercial relevance. A proposal to validate a prototype against a competitor's product gets treated like a research proposal, reviewed on novelty, not on market logic.

There's also a structural confusion about who owns this work. Is it the TTO? The research office? A separate innovation hub? At institutions without a clear answer, POC funding falls between organizational boundaries. Inventors wait. Opportunities age out.

graph TD
    A[Lab Discovery] --> B{Commercially Viable?}
    B -->|No clear answer| C[Technology Stalls]
    B -->|POC Funding Applied| D(De-risking Milestones)
    D --> E[Licensable or Investable Asset]
    E --> F(Licensing Deal)
    E --> G(Spinout Formation)

What a Good POC Program Looks Like

The institutions doing this well share a few traits worth naming.

First, they treat POC awards like early-stage investments, not grants. That means defining success criteria before funding starts, not after. It means shorter timelines with real checkpoints. It means someone with market knowledge is involved in the decision, not just faculty peers.

Second, they keep the amounts modest and the process fast. The sweet spot for most POC awards is $25,000 to $150,000. Enough to hire a postdoc for targeted validation work; not so much that the selection process becomes a multi-year bureaucratic exercise. Speed matters here. A licensing window can close in months.

Third, and this is the part that often gets skipped, they connect POC recipients to external stakeholders early. Not at the end, as a reward for completing milestones, but during the process. Industry advisors, potential pilot partners, even skeptical investors who can stress-test assumptions while there's still time to adjust. The feedback loop is the point.

The Real Cost of Not Having This

Every year, universities file patents on technologies that will never be licensed, not because they lack merit, but because no one ever answered the basic feasibility questions a licensee would ask. Those patents cost money to prosecute, money to maintain, and eventually get abandoned. The technology that could have supported a company, or solved a real problem somewhere, disappears into a database.

POC funding isn't glamorous. It doesn't generate the press releases that licensing deals do. But if you're trying to understand why some institutions consistently produce spinouts and attract industry partners while others struggle, look at what they're doing between discovery and deal. That's usually where the answer lives.